Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Inclusion Criteria:

- Adult subjects with inadequate response to >/= 2 non-steroidal antiinflammatories
(NSAIDs)

- Subject with axial SpA fulfilling the Assessment of Spondyloarthritis international
Society (ASAS) axial SpA classification criteria

- Subject with evidence of active inflammation in the sacroiliac (SI) joints or spine
on MRI, or elevated hs-CRP

- Negative TB screening assessment

- Ability to administer subcutaneous injections

- General good health otherwise

Exclusion Criteria:

- Prior anti-Tumor Necrosis Factor (TNF) therapy; biologic therapy with a potential
therapeutic impact on SpA or treated with an investigational drug of chemical or
biologic nature within 30 days or 5 half-lives of baseline.

- Fulfillment of the radiographic criterion of the modified New York criteria for
Ankylosing Spondylitis

- Recent infection requiring treatment

- Significant medical events or conditions that may put patients at risk for
participation

- Female subjects who are pregnant or breast-feeding or considering becoming pregnant
during the study